iBio, Inc. (IBIO) Income Statement
IBIO FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsIBIO revenue and net income
Where IBIO's revenue goes
FY2026Each bar shows an amount and its share of revenue. IBIO kept −33,044.0% of revenue as net income.
IBIO profit margins
IBIO growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −75.0% | +26.0% | −46.9% | −20.1% |
| Gross profit | −75.0% | +26.0% | −35.7% | −20.1% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IBIO quarterly EPS vs estimates
iBio beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.06).
IBIO income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100,000 | $400,000 | $225,000 | $50,000 | $1.9M | $2.4M | $1.6M | $2.0M | $444,000 | $394,000 |
| Cost of revenue | $1.0M | $0 | $1.2M | $1.1M | $3.8M | $1.5M | $703,000 | $0 | $13.0M | $13.0M |
| Gross profit | $100,000 | $400,000 | $225,000 | $50,000 | −$1.9M | $909,000 | $935,000 | $2.0M | $444,000 | $394,000 |
| Research & development | $19.6M | $8.3M | $5.2M | $10.3M | $9.8M | $10.0M | $3.6M | $5.5M | $4.0M | $4.1M |
| Sales, general & admin | $10.6M | $10.7M | $11.7M | $19.0M | $21.8M | $21.9M | $11.4M | $12.3M | $10.7M | $10.6M |
| Total operating expenses | $35.2M | $19.0M | $16.9M | $29.3M | $27.8M | $32.0M | $14.9M | $17.8M | $14.7M | $14.7M |
| Operating income | −$35.1M | −$18.6M | −$16.6M | −$29.3M | −$29.7M | −$31.1M | −$14.0M | −$15.8M | −$14.2M | −$14.3M |
| Interest income | $2.1M | $437,000 | $363,000 | $213,000 | $178,000 | $140,000 | $15,000 | $75,000 | $15,000 | $39,000 |
| Interest expense | $53,000 | $212,000 | $172,000 | $83,000 | $1.4M | $2.5M | $2.5M | $1.9M | $1.9M | $1.9M |
| Income before taxes | −$33.0M | −$18.4M | −$15.4M | −$29.3M | −$29.5M | −$23.2M | −$16.4M | −$17.6M | −$16.1M | −$14.5M |
| Income taxes | — | — | $9.6M | −$1.2M | $701,000 | $46,000 | $2.5M | −$4,000 | $34,000 | $347,000 |
| Net income | −$33.0M | −$18.4M | −$24.9M | −$29.3M | −$50.4M | −$23.2M | −$16.4M | −$17.6M | −$16.1M | −$14.5M |
| EBITDA | −$32.0M | −$17.0M | −$14.0M | −$28.1M | −$25.7M | −$28.6M | −$11.7M | −$13.9M | −$12.5M | −$12.5M |
| EPS (diluted) | −$0.48 | −$1.75 | −$6.42 | −$147.00 | −$57.96 | −$50.95 | −$43.70 | −$0.94 | −$1.56 | −$1.64 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | −101.2% | 38.3% | 57.1% | 100.0% | 100.0% | 100.0% |
| Operating margin | −35,141.0% | −4,650.5% | −7,392.9% | −58,622.0% | −1,576.3% | −1,312.1% | −854.9% | −782.4% | −3,204.3% | −3,622.8% |
| Net margin | −33,044.0% | −4,594.2% | −11,069.8% | −58,622.0% | −2,674.7% | −978.8% | −1,003.6% | −871.8% | −3,627.3% | −3,688.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $100,000 | $200,000 | $0 | $200,000 | $0 | $175,000 | $0 | $0 | $50,000 |
| Cost of revenue | −$780,000 | $250,000 | $241,000 | $289,000 | $0 | — | $0 | — | $281,000 | $332,000 | $387,000 | $250,000 |
| Gross profit | $780,000 | −$250,000 | −$241,000 | −$189,000 | $200,000 | — | $200,000 | — | −$106,000 | −$332,000 | −$387,000 | −$200,000 |
| Research & development | $8.6M | $3.3M | $4.3M | $3.5M | $3.2M | $1.9M | $1.9M | $1.3M | $1.1M | $904,000 | $1.5M | $1.6M |
| Sales, general & admin | $2.2M | $5.1M | $5.2M | $2.5M | $2.2M | $3.0M | $2.7M | $2.8M | $2.4M | $2.7M | $3.0M | $3.5M |
| Total operating expenses | $17.2M | $5.6M | $6.7M | $5.8M | $5.4M | $4.9M | $4.6M | $4.1M | $3.3M | $3.6M | $4.5M | $4.9M |
| Operating income | −$16.4M | −$5.9M | −$6.9M | −$6.0M | −$5.2M | −$4.9M | −$4.4M | −$4.1M | −$3.4M | −$3.6M | −$4.5M | −$5.1M |
| Interest income | $733,000 | $657,000 | $493,000 | $267,000 | $79,000 | $72,000 | $112,000 | $174,000 | $223,000 | $43,000 | $42,000 | $55,000 |
| Interest expense | $46,000 | $22,000 | $41,000 | $36,000 | $44,000 | $54,000 | $57,000 | $57,000 | $60,000 | $52,000 | $34,000 | $26,000 |
| Income before taxes | −$10.6M | −$7.7M | −$9.0M | −$5.7M | −$5.2M | −$4.9M | −$4.4M | −$4.0M | −$3.2M | −$2.6M | −$4.5M | −$5.1M |
| Income taxes | — | — | — | — | — | — | — | −$4.0M | −$1.3M | $537,000 | $34,000 | $727,000 |
| Net income | −$10.6M | −$7.7M | −$9.0M | −$5.7M | −$5.2M | −$4.9M | −$4.4M | −$4.0M | −$7.8M | −$3.2M | −$8.2M | −$5.7M |
| EBITDA | −$10.4M | −$7.5M | −$8.7M | −$5.4M | −$4.8M | −$4.5M | −$4.0M | −$3.7M | −$2.9M | −$2.3M | −$4.1M | −$4.7M |
| EPS (diluted) | −$0.04 | −$0.06 | −$0.09 | −$0.29 | −$0.32 | −$0.49 | −$0.48 | −$0.46 | −$0.90 | −$0.85 | −$4.42 | −$0.24 |
| Gross margin | — | — | — | −189.0% | 100.0% | — | 100.0% | — | −60.6% | — | — | −400.0% |
| Operating margin | — | — | — | −5,951.0% | −2,599.0% | — | −2,209.5% | — | −1,948.0% | — | — | −10,206.0% |
| Net margin | — | — | — | −5,720.0% | −2,581.5% | — | −2,182.0% | — | −4,444.6% | — | — | −11,492.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IBIO's financial statements (latest annual report filed August 28, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IBIO financial results
In fiscal year 2026 (ended June 30, 2026), iBio reported revenue of $0.1 million, down 75.0% from the year before. It had a net loss of $33.0 million, a net profit margin of −33,044.0%. Diluted earnings per share came to −$0.48. Over five years revenue grew at an average rate of −46.9% a year.
See the IBIO stock overview for the latest quote and news, or the IBIO chart for price history and technical indicators.
IBIO income statement FAQ
What is iBio's annual revenue?
iBio reported total revenue of $0.1 million for fiscal year 2026, which ended on June 30, 2026. That was down 75.0% from $0.4 million the previous year.
Is iBio profitable?
No. iBio reported a net loss of $33.0 million in fiscal 2026, a net profit margin of −33,044.0%; its operating margin was −35,141.0%.
What is iBio's gross margin?
iBio's gross margin was 100.0% in fiscal 2026: for every $100 of revenue, iBio kept $100 after the direct cost of its products and services.
How much does iBio spend on research and development?
iBio spent $19.6 million on research and development in fiscal 2026, 19,643.0% of revenue.
How fast is iBio growing?
Revenue grew −46.9% a year on average over the last five fiscal years, from $2.4 million to $0.1 million.
What are iBio's earnings per share?
iBio earned $-0.48 per diluted share in fiscal 2026, compared with $-1.75 a year earlier.
When will iBio report its next earnings?
iBio is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does iBio's fiscal year end?
iBio's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 28, 2026.